Document:

<PAGE>

                                                                   EXHIBIT 10.14

                               LICENSE AGREEMENT

THIS AGREEMENT, dated as of May 18, 2000 ("Effective Date"), is between Advanced
Life Sciences, Inc. ("Licensor"), 12305 South New Avenue, Lemont, Illinois
60439, and MediChem Research, Inc., ("Licensee"), 12305 South New Avenue,
Lemont, Illinois 60439, and shall modify and amend the previous Agreement dated
October 31, 1999.

                                  WITNESSETH

WHEREAS, Licensor represents that it owns the rights to offer for sale, sell,
make, and use the patent entitled "Biflavanoids and Derivatives Thereof as
Antiviral Agents" (U.S. Patent No.: 5,948,918 granted September 7, 1999), and
owns and controls all rights relating to the Licensed Technical Information
(hereinafter defined); and

WHEREAS, Licensee desires to receive, and Licensor desires to grant to Licensee
exclusive rights under such patent and to such technical information in the
Licensed Territory (hereinafter defined), and Licensee desires to accept such
rights, in accordance with the terms set forth below.

NOW, THEREFORE, intending to be legally bound, the parties hereby agree as
follows:

1. Definitions

     1.1 "Licensed Patent" means the patent entitled "Biflavanoids and
     Derivatives Thereof as Antiviral Agents." The Licensed Patent shall include
     all improvements, divisionals, continuations, continuations-in-part, re-
     examinations, and reissues thereof.

     1.2 "Licensed Technical Information" means unpublished research and
     development information, unpatented inventions, know-how, trade secrets,
     and technical information relevant to the Licensed Patent in the possession
     of Licensor or any of its Affiliates (hereinafter defined) at the Effective
     Date of this Agreement.

     1.3 "Exclusive License" means a license granting Licensee the manufacture
     the Licensed Products (hereinafter defined), to the exclusion of all other
     parties including Licensor.

     1.4 "Licensed Products" means any products derived from the use,
     development to and/or the improvement of the Licensed Patent.

     1.5 "Licensed Territory" means the United States of America.

     1.6 "Affiliate" means, with respect to each party, any corporation or other
     legal entity that directly or indirectly controls, is controlled by, or is
     under common control with, the party, but only for so long as said control
     continues. For purposes of this definition, "control" means the power,
     whether or not normally exercised, to direct the management and affairs of
     another corporation or other legal entity, directly or indirectly, whether
     through the ownership of voting securities, by contract or otherwise. In
     the case of a corporation, the direct or indirect ownership of fifty
     percent (50%) or more of its outstanding voting shares shall in any case be
     deemed to confer control, provided that the direct or indirect ownership of
     a lower percentage of such securities shall not necessarily preclude the
     existence of control.
<PAGE>

     1.7 "Net Sales" shall mean the total gross receipts for sales of Licensed
     Products by or on behalf of Licensee or its sublicensees, and from selling,
     leasing, renting or otherwise making Licensed Products available to others
     whether invoiced or not, less returns and allowances actually granted in
     the normal course of business including but not limited to trading, packing
     costs, insurance costs, freight out, taxes or excise duties imposed on the
     transaction (if separately invoiced), and wholesale and cash discounts in
     amounts customary in the trade. No deductions shall be made for commissions
     paid to individuals, whether they be with independent sales agencies or
     regularly employed by Licensee, or sublicensee, and on its payroll, or for
     the cost of collections.

2. Confidentiality

     2.1. Licensee will hold Licensor's Confidential Information in the
     strictest confidence using such reasonable measures as it uses to protect
     the confidentiality of similar information belonging to it. All written (or
     otherwise recorded) originals and copies of confidential information must
     be returned to Licensor with the exception of one copy being reserved for
     file purposes only. The parties will use Confidential Information solely to
     perform the activities under this Agreement and will disclose Confidential
     Information only to their employees or contractors with a need to know such
     information. Notwithstanding the other provisions of this Agreement,
     nothing received by Licensee shall be considered Licensor's Confidential
     Information which (a) is now available or becomes available to the public
     without breach of this Agreement, (b) is released in writing by Licensor,
     (c) is lawfully obtained from a third party or parties, (d) is known to the
     Licensee prior to such disclosure, or (e) is at any time developed by
     Licensee independent of such disclosure. Licensor further agrees to release
     Licensee from any duty of confidentiality after seven (7) years have
     expired from the time of termination of the agreement.

3. Warranty of Title

     3.1. Licensor represents and warrants it is the sole owner of the Licensed
     Patent, and that it has the right to grant the License described in this
     Agreement.

4. License Grant

     4.1 Licensor grants to the Licensee an exclusive license to offer for sale,
     make, use, and sell the Licensed Patent in the Licensed Territory. Licensee
     shall have the right to assign and/or sublicense, in part or in whole, the
     Licensed Patent and/or the Licensed Technical Information, and shall have
     the right to procure manufacturing from third party contractors who are
     bound by confidentiality terms at least as strong as in this Agreement.
     Licensor shall, within thirty (30) days of the effective date of this
     Agreement make available to Licensee for its use the Licensed Technical
     Information in Licensor's possession needed to make the Licensed Products.

     4.2 Licensor agrees to keep Licensee fully and promptly informed of the
     status of the prosecution of the Licensed Patent and (c) consult with
     Licensee on all aspects of the prosecution of this application.

5. Patent Infringement

     5.1 In the event of third party infringement of the Licensed Patent in the
     Licensed Territory, the parties will develop a mutually acceptable plan for
     abatement of the infringement and shall contribute toward attorney's fees
     and costs in proportion to the loss of royalties or profits being caused by
     the infringement. In any lawsuit for infringement, both parties shall be
     named as plaintiffs,

                                       2
<PAGE>

     Licensor shall control all aspects of the lawsuit, and any award or
     settlement shall be divided in proportion to each party's loss of royalties
     or profits.

6. Indemnification

     6.1 Licensee agrees to defend, indemnify, and hold Licensor harmless
     against all claims and actions as a result of any sales, property damage,
     or personal injury sustained by Licensee, its employees, or other third
     parties, as a result of misuse of the Licensed Patent or the Licensed
     Technical Information. Licensee will carry adequate product liability
     insurance.

7. Royalties & Milestones

     7.1 Licensee will pay Licensor a royalty of eight percent (8%) of all Net
     Sales of any of the Licensed Products.

     7.2 Licensor agrees to pay Licensee a milestone payment of $400,000.00 upon
     demonstrated Commercial Use.

     7.3 Licensor agrees to pay Licensee a milestone payment of $400,000.000
     upon successful issuance of the Licensed Patent from the United States
     Patent and Trademark Office.

     7.4 Licensor agrees to pay Licensee a milestone payment of $100,000.000 for
     each publication in a Peer Reviewed Journal.

8. Intellectual Property

     8.1 Licensee agrees that Licensor will own all of the intellectual property
     rights that arise from Licensee inventions including developments to or
     improvements on the Licensed Patent.

9. Promotions and Marketing

     9.1 Both parties agree that, in promotions and marketing of the technology,
     Licensee and Licensor will use their names in conjunction with one another.

10. Term and Termination

     10.1. This Agreement may be terminated earlier by one or more of the
     following events:

       1. The mutual, written agreement of the Parties to terminate the
       Agreement;

       2. If a party to this Agreement makes a material breach of any provision
       herein, the non-breaching party will, in writing, provide the breaching
       party thirty days (30) to cure the breach.

       If not cured within the thirty-day period, the non-breaching party can,
       in writing, terminate this Agreement;

       3. The filing for bankruptcy, the acquisition, or the sale of a party to
       this Agreement will result in the termination of this Agreement; or

       5. The Licensed Patent expires.

11. Best Efforts

     11.1 Licensee agrees to use its best efforts to sell any of the Licensed
     Products in the Licensed Territory.

                                       3
<PAGE>

12. Applicable Law

     12.1 The applicable law governing any cause of action arising out of this
     Agreement, or the performance by a party hereto, shall be governed by the
     laws of the United States of America and the State of Illinois.

13. Severability

     13.1 If any one or more of the provisions of this Agreement shall be held
     to be invalid, illegal or unenforceable, the validity, legality or
     enforceability of the remaining provisions of this agreement shall not in
     any way be affected or impaired thereby.

14. Miscellaneous

     14.1 Nothing contained herein, or done in pursuance of this Agreement,
     shall constitute the parties as entering into a legal partnership, joint
     venture, or any other business entity or business relationship other than
     that expressly described in this Agreement, or shall constitute a party
     hereto the agent for the other party for any purpose or in any sense
     whatsoever. This Agreement embodies the entire understanding of the parties
     with respect to the subject matter contained herein and shall supersede all
     previous communications, representations or understandings, either oral or
     written, between the parties relating to the subject matter hereof. No
     amendment or modification of this Agreement shall be valid or binding upon
     the parties unless signed by their respective duly authorized officers.

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be
executed by its duly authorized officer or representative as of the date set
forth below.

Advanced Life Sciences, Inc.                 MediChem Research, Inc.

___________________________                  ____________________________
Michael T. Flavin, Ph.D.                     John L.Flavin
President and CEO                            Executive Vice President

___________________________                  ____________________________
Date                                         Date

                                       4<PAGE>

                                                                   EXHIBIT 10.15

                               LICENSE AGREEMENT

     THIS AGREEMENT, dated as of May 4, 2000, is between MediChem Research,
Inc., ("Licensee"), and Advanced Life Sciences, Inc., ("Licensor"), and shall
modify and amend the previous Agreement dated July 1, 1999, between MediChem
Research, Inc., ("Licensee"), and Advanced Life Sciences, Inc., ("Licensor").

                                  WITNESSETH

     WHEREAS, Licensor represents that it has applied for the patent entitled
"Use of Automated Technology In Chemical Process Research And Development" (U.S.
Patent Application Number 08/862,840), and owns and controls know-how rights
relating to the Licensed Technical Information (hereinafter defined); and

     WHEREAS, Licensee desires to receive, and Licensor desires to grant to
Licensee exclusive rights under such patent and to such technical information in
the Licensed Territory (hereinafter defined), and Licensee desires to accept
such rights, in accordance with the terms set forth below.

     NOW, THEREFORE, intending to be legally bound, the parties hereby agree as
follows:

1.   Definitions

     1.1  "Licensed Patent" means the patent entitled "Use of Automated
     Technology In Chemical Process Research And Development" (U.S. Patent
     Number: 6044212). The Licensed Patent shall include all divisionals,
     continuations, continuations-in-part, re-examinations, and reissues
     thereof.

     1.2  "Licensed Technical Information" means unpublished research and
     development information, unpatented inventions, know-how, trade secrets,
     and technical information relevant to the Licensed Patent in the possession
     of Licensor or any of its Affiliates (hereinafter defined) at the Effective
     Date of this Agreement.

     1.3  "Exclusive License" means a license granting Licensee the right to
     make, use and sell the Licensed Products (hereinafter defined), to the
     exclusion of all other parties including Licensor.

     1.4  "Licensed Products" means any products derived from the use,
     development to and/or the improvement of the Licensed Patent.

     1.5  "Licensed Territory" means all the countries of the world.

     1.6  "Affiliate" means, with respect to each party, any corporation or
     other legal entity that directly or indirectly controls, is controlled by,
     or is under common control with, the party, but only for so long as said
     control continues. For purposes of this definition, "control" means the
     power, whether or not normally exercised, to direct the management and
     affairs of another corporation or other legal entity, directly or
     indirectly, whether through the ownership of voting securities, by contract
     or otherwise. In the case of a corporation, the direct or indirect
     ownership of fifty percent (50%) or more of its outstanding voting shares
     shall in any case be deemed to confer control, provided that the direct or
     indirect ownership of a lower percentage of such securities shall not
     necessarily preclude the existence of control.
<PAGE>

     1.7  Effective Date shall mean the date upon which both parties sign the
     agreement.

     1.8  "Net Sales" shall mean the total gross receipts for sales of Licensed
     Products by or on behalf of Licensee or its sublicensees, and from selling,
     leasing, renting or otherwise making Licensed Products available to others
     whether invoiced or not, less returns and allowances actually granted in
     the normal course of business including but not limited to trading, packing
     costs, insurance costs, freight out, taxes or excise duties imposed on the
     transaction (if separately invoiced), and wholesale and cash discounts in
     amounts customary in the trade. No deductions shall be made for commissions
     paid to individuals, whether they be with independent sales agencies or
     regularly employed by Licensee, or sublicensee, and on its payroll, or for
     the cost of collections.

     1.9  "Commercial Use" shall mean the satisfactory completion of an
     automated process research project conducted under contract for a customer
     of the Licensee.

     1.10 "Peer Reviewed Journal" shall include any scientific, biotechnology,
     and/or pharmaceutical related journal in which manuscripts are reviewed and
     approved by a board of editors.

2.   Confidentiality

     2.1. Licensee will hold Licensor's Confidential Information in the
     strictest confidence using such reasonable measures as it uses to protect
     the confidentiality of similar information belonging to it. All written (or
     otherwise recorded) originals and copies of confidential information must
     be returned to Licensor with the exception of one copy being reserved for
     file purposes only. The parties will use Confidential Information solely to
     perform the activities under this Agreement and will disclose Confidential
     Information only to their employees or contractors with a need to know such
     information. Notwithstanding the other provisions of this Agreement,
     nothing received by Licensee shall be considered Licensor's Confidential
     Information which (a) is now available or becomes available to the public
     without breach of this Agreement, (b) is released in writing by Licensor,
     (c) is lawfully obtained from a third party or parties, (d) is known to the
     Licensee prior to such disclosure, or (e) is at any time developed by
     Licensee independent of such disclosure. Licensor further agrees to release
     Licensee from any duty of confidentiality after seven (7) years have
     expired from the time of termination of the agreement.

3.   Warranty of Title

     3.1. Licensor represents and warrants it is the sole owner of the Licensed
     Patent and the Licensed Technical Information, and that it has the right to
     grant the License described in this Agreement.

4.   License Grant

     4.1  Licensor grants to the Licensee an exclusive license to use the
     Licensed Patent and assign the Licensed Technical Information in the
     Licensed Territory. Licensor further agrees to grant to Licensee an
     exclusive license under the Licensed Patent to make, use, and sell the
     Licensed Products, in and into the Licensed Territory. Licensee shall have
     the right to sublicense, in part or in whole, the Licensed Patent or
     Licensed Technical Information, and shall have the right to procure
     manufacturing from third party contractors who are bound by confidentiality
     terms at least as strong as in this Agreement. Licensor shall, within
     thirty (30) days of the effective date of this Agreement make available to
     Licensee for its use the Licensed Technical Information in Licensor's
     possession needed to make the Licensed Products.

     4.2  Licensor agrees to keep Licensee fully and promptly informed of the
     status of the prosecution of

                                       2
<PAGE>

     the Licensed Patent and (c) consult with Licensee on all aspects of the
     prosecution of this application.

5.   Patent Infringement

     5.1  In the event of third party infringement of the Licensed Patent in the
     Licensed Territory, the parties will develop a mutually acceptable plan for
     abatement of the infringement and shall contribute toward attorney's fees
     and costs in proportion to the loss of royalties or profits being caused by
     the infringement. In any lawsuit for infringement, both parties shall be
     named as plaintiffs, Licensor shall control all aspects of the lawsuit, and
     any award or settlement shall be divided in proportion to each party's loss
     of royalties or profits.

6.  Technical Assistance by Licensor

     6.1  Licensor will provide consulting services related to process described
     in the Licensed Patent upon request of Licensee.

7.   Indemnification

     7.1  Licensee agrees to defend, indemnify, and hold Licensor harmless
     against all claims and actions as a result of any sales, property damage,
     or personal injury sustained by Licensee, its employees, or other third
     parties, as a result of use of the Licensed Patent or the Licensed
     Technical Information. Licensee will carry adequate product liability
     insurance.

8.   Royalties & Milestones

     8.1  Licensee will pay Licensor a royalty of eight percent (8%) of all Net
     Sales of any of the Licensed Products.

     8.2  Licensor agrees to pay Licensee a milestone payment of $400,000.00
     upon demonstrated Commercial Use.

     8.3  Licensor agrees to pay Licensee a milestone payment of $400,000.000
     upon successful issuance of the Licensed Patent from the United States
     Patent and Trademark Office.

     8.4  Licensor agrees to pay Licensee a milestone payment of $200,000.000
     for each publication in a Peer Reviewed Journal.

9.   Intellectual Property

     9.1  Licensee agrees that Licensor will own all of the intellectual
     property rights that arise from Licensee inventions including developments
     to or improvements on the Licensed Patent.

10.  Promotions and Marketing

     10.1 Both parties agree that, in promotions and marketing of the
     technology, Licensee and Licensor will use their names in conjunction with
     one another.

11.  Term and Termination

                                       3
<PAGE>

     11.1. This Agreement may be terminated earlier by one or more of the
     following events:

     1. The mutual, written agreement of the Parties to terminate the Agreement;

     2. If a party to this Agreement makes a material breach of any provision
     herein, the non-breaching party will, in writing, provide the breaching
     party thirty days (30) to cure the breach.

     If not cured within the thirty-day period, the non-breaching party can, in
     writing, terminate this Agreement;

     3. The filing for bankruptcy, the acquisition, or the sale of a party to
     this Agreement will result in the termination of this Agreement; or

     5. The Licensed Patent expires.

12.  Applicable Law

     12.1 The applicable law governing any cause of action arising out of this
     Agreement, or the performance by a party hereto, shall be governed by the
     laws of the United States of America and the State of Illinois.

13.  Severability

     13.1 If any one or more of the provisions of this Agreement shall be held
     to be invalid, illegal or unenforceable, the validity, legality or
     enforceability of the remaining provisions of this agreement shall not in
     any way be affected or impaired thereby.

14.  Miscellaneous

     14.2 Nothing contained herein, or done in pursuance of this Agreement,
     shall constitute the parties as entering into a legal partnership, joint
     venture, or any other business entity or business relationship other than
     that expressly described in this Agreement, or shall constitute a party
     hereto the agent for the other party for any purpose or in any sense
     whatsoever. This Agreement embodies the entire understanding of the parties
     with respect to the subject matter contained herein and shall supersede all
     previous communications, representations or understandings, either oral or
     written, between the parties relating to the subject matter hereof. No
     amendment or modification of this Agreement shall be valid or binding upon
     the parties unless signed by their respective duly authorized officers.

IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be
executed by its duly authorized officer or representative as of the date set
forth below.

                                       4
<PAGE>

Advanced Life Sciences, Inc.                MediChem Research, Inc.

__________________________                  ______________________________
Michael T. Flavin, Ph.D.                    John L. Flavin
President and CEO                           Vice President of Operations

__________________________                   _____________________________
Date                                         Date

                                       5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00011-of-00352.parquet"}]]